Guardant Health, Inc. (GH) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 30 analysts11.5% Below Target
GH trades 11.5% below Wall Street's consensus target of $147.00.
Current Price$131.78
Average Target$147.00
Target
Current
Low$115.00
Median$135.00
High$185.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth+11.1%
(Moderate)
Analyst Spread47.6%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes GH achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 30 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
GH Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Guardant Health, Inc. (GH) has a Wall Street consensus price target of $147.00, based on estimates from 30 covering analysts. With the stock currently trading at $131.78, this represents a potential upside of +11.5%. The company has a market capitalization of $17.47B.
Analyst price targets range from a low of $115.00 to a high of $185.00, representing a 48% spread in expectations. The median target of $135.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 29 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GH trades at a trailing P/E of -39.7x. Analysts expect EPS to grow +11.1% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+45.0%
Industry Consensus
Avg Forward P/E
136.3x
(High Premium)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
 NTRANatera, Inc. | $33.1B | $231.41 | $259.88 | +12.3% | Buy | — | 27 |
 FDMT4D Molecular Therapeutics, Inc. | $505M | $9.66 | $33.00 | +241.6% | Buy | — | 14 |
 CGENCompugen Ltd. | $190M | $2.01 | $4.50 | +123.9% | Buy | — | 14 |
 PACBPacific Biosciences of California, Inc. | $435M | $1.40 | $1.00 | -28.6% | Buy | — | 18 |
 CDNACareDx, Inc | $1.4B | $26.18 | $27.00 | +3.1% | Buy | 28.0x | 13 |
 BNGOBionano Genomics, Inc. | $4M | $1.17 | — | — | — | — | — |
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
 DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
GH — Frequently Asked Questions
Quick answers to the most common questions about buying GH stock.
What is the GH stock price target for 2026?
Guardant Health, Inc. (GH) has a consensus 12-month price target of $147, implying 11.5% upside from $131.78. The 30 analysts covering GH see moderate appreciation potential.
Is GH a buy, sell, or hold?
GH has a consensus rating of "Buy" based on 30 Wall Street analysts. The rating breakdown is predominantly bullish, with 29 Buy/Strong Buy ratings. The consensus 12-month price target of $147 implies 11.5% upside from current levels.
Is GH stock overvalued or undervalued?
GH's current price is $131.78 with a consensus target of $147 (11.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can GH stock go?
The most bullish Wall Street analyst has a price target of $185 for GH, while the most conservative target is $115. The consensus of $147 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover GH stock?
GH is heavily covered by Wall Street, with 30 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 29 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GH stock forecast?
The 12-month GH stock forecast based on 30 Wall Street analysts shows a consensus price target of $147, with estimates ranging from $115 (bear case) to $185 (bull case). The median consensus rating is "Buy".
Should I buy GH stock?
Wall Street analysts are optimistic on GH, with a "Buy" consensus rating and $147 price target (11.5% upside). 29 of 30 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GH price targets vary so much?
GH analyst price targets range from $115 to $185, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $147 consensus represents the middle ground.
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into GH consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare